Cline Scientific AB (publ)

As of June 30, 2021, Cline Scientific AB (publ) has 19.06M shares outstanding.

These figures are as of June 30, 2021. The price-to-sales ratio is 2,950.94, and the price-to-book ratio stands at -6.06.

These figures are as of June 30, 2021. The EV/Sales ratio of 2,638.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2021, Cline Scientific AB (publ) maintains a current ratio of 14.61, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2021. Return on assets (ROA) is negative at -20.62, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 23.44, useful for judging operating efficiency across full business cycles.

As of the close on September 3, 2024, Cline Scientific AB (publ)'s stock has declined approximately 66.99% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.14.

Over the twelve months ended June 30, 2021, Cline Scientific AB (publ) posted a gross margin of 7,624.13, reflecting its pricing power and cost economics. The operating margin of -9,716.36 and net profit margin of -9,795.42 provide insight into operational efficiency.

Cline Scientific AB (publ)'s most recent stock split took place on June 16, 2023 with a 163:201 split ratio.

As of June 30, 2021, Cline Scientific AB (publ) has an Altman Z-Score of 34.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.